Menu ×


Oligonucleotide API Market Analysis by Product type {Reagents & Consumables, and Equipment & Synthesized (DNA Oligonucleotides, RNA Oligonucleotides, and Others)}; by Marketing Status (Marketed and Clinical Trials); and by End User (Pharmaceutical Companies and Biotechnology Companies) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  •  Ionis Pharmaceuticals, Inc. in collaboration with Biogen Inc., has announced the results of the investigation of the use of antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS).

  • Jazz Pharmaceuticals plc has announced that its Zepzelca (Lurbinectedin) has been approved by the U.S. Food and Drug Administration(FDA), for treating adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Global Oligonucleotide API Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 2 Billion

Forecast Year Market Size (2035)

~ USD 5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)


The global oligonucleotide API market is estimated to garner a revenue of USD 5 Billion by the end of 2035 by growing at a CAGR of ~10% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of USD 2 Billion in the year 2022. The growth of the market is primarily attributed to the rise in laboratory and research institute experiments worldwide. This Increasing use of oligonucleotides for various applications such as gene editing, diagnostics, therapeutics, and agriculture has driven the surge in interest in APIs across organizations. As per the data by the World Bank, as of 2018, there were 1597 researchers per 1,000,000 people involved in research and development activities, an increase from 1412 researchers per million in 2015.

oligonucleotide market overview Get more information on this report:Request Sample PDF

The oligonucleotide is a new type of therapeutic molecule ideal for treating a variety of diseases. Oligonucleotide base pairs with DNA or RNA to form a structure. In PCR (polymerase chain reaction), oligonucleotides are commonly used as primers. In addition, funding in life science activities, innovative product launches, and drug discovery, along with investments in high-profile big science projects are expected to drive demand for oligonucleotide API during the forecast period. According to estimates, governments around the world and international organizations are expected to invest a total of more than USD 170 billion on large-scale science projects between 2022 and 2025.

Global Oligonucleotide API Market: Growth Drivers and Challenges

Growth Drivers

  • Globally Rising Prevalence of Cancer and Neurodegenerative Diseases - Based on data from the National Cancer Institute, as of 2020, there were 1,806,590 new cancer diagnoses in the United States and 606,520 cancer deaths. The rising number of cancer cases is propelling the demand for advanced testing procedures. Moreover, the treatment of neurodegenerative diseases requires a personalized approach as well. In terms of neurodegenerative conditions, Alzheimer's disease is one of the most common. There are several limitations associated with conventional medicine in this area, so oligonucleotide APIs are being studied extensively. This factor is expected to expand the global oligonucleotide API market size during the forecast period

  • Growth in Percentage of API Manufacturing Facilities in Emerging Countries - According to the US Food & Drug Administration, there are more than 28% of API manufacturing facilities based in the United States in 2019 catering to the market in the US. 59 % are located in other regions, including 13 percent in China.

  • Increase in Medical Approvals for Oligonucleotides - It was observed that as of 2019, 605 oligonucleotide approval programs were in development, compared with only 200 in 2010. 

  • Growing Expenditures on Healthcare Throughout the World - Global healthcare expenditure accounted for 9.83 billion in 2019 according to data provided by the World Bank, an increase from 9.7 billion in 2018.

  • Rising per Capita Income Worldwide - The World Bank reported that worldwide annual per capita income increased by 4.8% in 2021, up from 1.5% in 2019.


  • High Production Costs Associated with Oligonucleotide - The current state of the art in oligonucleotide synthesis provides a waste and expense burden to firms, with just 12 oligonucleotide pharmaceuticals having reached the market to date and hundreds more being developed in medical studies and preclinical research. So, every waste from the reversed-phase purification process comprises an organic solvent, and using it entails paying for hazardous waste disposal. Solvent recovery is economically and environmentally advantageous at high production volumes, but around 50% of the waste volume still needs to be disposed of as aqueous-rich hazardous waste. 

  • Complex Procedure for Manufacturing

  • Mandatory Good Manufacturing Practice Guidelines and Product Licensing

The global oligonucleotide API market is segmented and analyzed for demand and supply by end-user into pharmaceutical companies and biotechnology companies. Among these segments, the pharmaceutical companies segment is anticipated to capture the largest market size in the global oligonucleotide API market during the forecast period owing to the increasing adoption of innovative technology by pharmaceutical giants for improving drug efficacy and reducing development costs. For instance, a variety of oligonucleotides has become increasingly popular in the pharmaceutical industry, including antisense oligonucleotides, short-interfering RNAs, splice-switching oligonucleotides, microRNAs, immunostimulatory oligonucleotides, aptamers. The capacity to target the illness gene or the messenger RNAs (mRNAs) that are encoded by it has created new therapeutic possibilities. The length of therapeutic antisense oligonucleotides (ASOs) varies from 18 to 30 base pairs (bp).

Global Oligonucleotide API Market Regional Synopsis

The North America oligonucleotide API market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. Increasing R&D investments in drug discovery and commercialization of oligonucleotide therapies are expected to drive the regional market during the forecast period. Moreover, increased healthcare spending along with enhanced healthcare facilities are further anticipated to fuel the oligonucleotide API market in the region over the forecast period. A recent report from the Centers for Medicare & Medicaid Services revealed that approximately 19.7% of GDP in the United States was spent on healthcare services in 2020, amounting to USD 4.1 trillion in total.

oligonucleotide market share

Market Segmentation

Our in-depth analysis of the global oligonucleotide API market includes the following segments:

        By Product Type

  • Reagents & Consumables
  • Equipment & Synthesized
    • DNA Oligonucleotides
    • RNA Oligonucleotides
    • Others

      By Marketing Status

  • Marketed
  • Clinical Trials

      By End User

  • Pharmaceutical Companies
  • Biotechnology Companies

Top Featured Companies Dominating the Global Oligonucleotide API Market

  • Ionis Pharmaceuticals, Inc.,

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Jazz Pharmaceuticals plc 
  • Biogen Inc.
  • Sarepta Therapeutics
  • Alnylam Pharmaceuticals, Inc.
  • Corden Pharma GmbH
  • Dynavax Technologies
  • GE Healthcare Life Sciences
  • Nitto Denko Avecia
  • STA Pharmaceutical Co. Ltd


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved